Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cells

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 3847-3853

  Izumiya, Motoko ^a   Kabashima, Ayano ^a   Higuchi, Hajime ^a   Igarashi, Toru ^a   Sakai, Gen ^a   Iizuka, Hideko ^a   Nakamura, Shoko ^a   Adachi, Masayuki ^a   Hamamoto, Yasuo ^a   Funakoshi, Shinsuke ^a   Takaishi, Hiromasa ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 Fluorouracil; Apoptosis; Cancer stem cells; Chemoresistance; EMT; Panc 1 cells; Pancreatic cancer

Indexed keywords

FLUOROURACIL; MATRIGEL; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VIMENTIN;

APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL INVASION; CELL RENEWAL; CELL SURVIVAL; CHEMOSENSITIVITY; CLINICAL EVALUATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; IMMUNOBLOTTING; INCUBATION TIME; PANCREAS CANCER; PANCREAS CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FLUOROURACIL; HOMEODOMAIN PROTEINS; HUMANS; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PANCREATIC NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84867000389     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Makrilia N, Syrigos KN and Saif MW: Updates on treatment of gemcitabine-refractory pancreatic adenocarcinoma. Highlights from the 2011 ASCO Annual Meeting. Chicago, IL, USA; June 3-7: 12(4): 351-354, 2011.
2. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D and Sarkar FH: Pancreatic cancer: Understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 8(1): 27-33, 2011.
3. Malik B and Nie D: Cancer stem cells and resistance to chemo and radio therapy. Front Biosci 4: 2142-2149, 2012.
4. Ni X, Long J, Cen P, Chen L, Yang J and Li M: Pancreatic cancer tumor initiating cells: The molecular regulation and therapeutic values. J Cell Mol Med 16 (5): 988-994, 2012.
5. Du Z, Qin R, Wei C, Wang M, Shi C, Tian R and Peng C: Pancreatic cancer cells resistant to chemoradiotherapy rich in stem-cell-like tumor cells. Dig Dis Sci 56(3): 741-750, 2011.
6. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU and Gallick GE: Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 14(12): 3629-3637, 2007. (Pubitemid 350160137)
7. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE and Sarkar FH: Acquisition of epithelial to mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the NOTCH signaling pathway. Cancer Res 69(6): 2400-2407, 2009.
8. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ and Choi W: Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Re 69(14): 5820-5828, 2009.
9. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, and Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4): 704-715, 2008. (Pubitemid 351636299)
10. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH and Nephew KP: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68(11): 4311-4320, 2008.
11. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139(5): 871-890, 2009.
12. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ and Heeschen C: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3): 313-323, 2007. (Pubitemid 47355323)
13. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification of pancreatic cancer stem cells. Cancer Res 67(3): 1030-1037, 2007.
14. Kabashima A, Higuchi H, Takaishi H, Matsuzaki Y, Suzuki S, Izumiya M, Iizuka H, Sakai G, Hozawa S, Azuma T and Hibi T: Side population of pancreatic cancer cells predominates in TGF-beta- mediated epithelial to mesenchymal transition and invasion. Int J Cancer 124(12): 2771-2779, 2009.
15. Zhang SN, Huang FT, Huang YJ, Zhong W and Yu Z: Characterization of a cancer stem cell-like side population derived from human pancreatic adenocarcinoma cells. Tumori 96(6): 985-992, 2010.
16. Zhou J, Wang CY, Liu T, Wu B, Zhou F, Xiong JX, Wu HS, Tao J, Zhao G, Yang M, and Gou SM: Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J Gastroenterol 14(6): 925-930, 2008. (Pubitemid 351325033)
17. Wigmore PM, Mustafa S, El-Beltagy M, Lyons L, Umka J and Bennett G: Effects of 5-FU. Adv Exp Med Biol 678: 157-164, 2010.
18. Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS, and Wu CW: Coexpression of OCT4 and NANOG enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 70(24): 10433-10444, 2010.
19. Glinsky GV: Stemness genomics law governs clinical behavior of human cancer: Implications for decision making in disease management. J Clin Oncol 27(17): 2846-2853, 2008.
20. Mathieu J, Zhang Z, Zhou W, Wang AJ, Heddleston JM, Pinna CM, Hubaud A, Stadler B, Choi M, Bar M, Tewari M, Liu A, Vessella R, Rostomily R, Born D, Horwitz M, Ware C, Blau CA, Cleary MA, Rich JN, and Ruohola-Baker H: HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 17(13): 4640-4652, 2011.